Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.

In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m-2 once every 3 weeks in an outpatien...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, S., Hanauske, A. R., Pavlidis, N., Bruntsch, U., te Velde, A., Wanders, J., Heinrich, B., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074426/
https://www.ncbi.nlm.nih.gov/pubmed/8562351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074426/
https://www.ncbi.nlm.nih.gov/pubmed/8562351

Ejemplares similares